Want to see BHST full AI Analyst Report?
BHST Stock Chart & Stats
$11.28
--
Market closed
$11.28
--
Day’s Range― - ―
52-Week Range$2.74 - $12.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)78.84K
Market Cap
$63.02M
Enterprise Value$54.08M
Total Cash (Recent Filing)$19.17M
Total Debt (Recent Filing)$16.42M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 31, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,667,843
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda-8.09
Forecast
1Y Price Target
$12.00Price Target Upside6.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$42.89M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Strong Gross MarginConsistent top-line growth and materially improved gross margins indicate durable product-market fit across D2C and CDMO channels. Higher gross margins create room to absorb SG&A while moving toward operating leverage if scale and conversion of VINIA users to repeat buyers continues.
Proprietary CDMO Milestones Driving High-value ContractsTechnological validation (stage completions) plus retained ownership stakes in compositions support a differentiated CDMO model with potential royalty streams. This structural advantage targets supply-constrained botanicals and can create high-margin, recurring revenues beyond one-off manufacturing fees.
Material Improvement In Liquidity PositionA substantially stronger cash balance provides runway to execute a deliberate marketing reset, fund CDMO project development, and advance facility planning without immediate reliance on dilutive financings. Better liquidity reduces short-term solvency risk while management pursues H2 2026/2027 growth milestones.
Bears Say
Persistent Net Losses And Negative Operating Cash FlowOngoing structural cash burn and negative free cash flow mean the company remains dependent on external financing or improved operational cash conversion to fund growth. Until operating cash flow sustainably turns positive, financing risk could constrain capacity expansion and increase dilution or leverage.
Capacity Expansion Timing And Capital UncertaintyScale of CDMO and royalty-driven plans hinge on a new manufacturing site coming online. Delays or underfunding would bottleneck production, impede commercial delivery for signed projects, and slow revenue ramp, creating execution risk and potential lost customer opportunities in high-value segments.
Early-stage Technical And Commercialization Risks For Novel AssetsDependence on nascent technologies and assets creates uncertainty around development timelines, processing costs, and regulatory or market acceptance. If key programs require extended validation or fail to scale economically, projected royalty and CDMO upside could be delayed or diminished, raising concentration risk.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was $2.74 and its highest was $12.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is $63.02M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Aug 31, 2026 which is in 49 days.
How were BioHarvest Sciences’s earnings last quarter?
Currently, no data Available
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.12.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (6.38% Upside)
$12.00 (6.38% Upside)
Blogger Sentiment
Neutral
BHST Sentiment 50%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
-88.01%
Trailing 12-Months
Asset Growth
71.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
BHST Stock 12 Month Forecast
Average Price Target
$12.00
▲(6.38% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
0.05% Mutual Funds
0.65% Other Institutional Investors
99.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---